A Study On The Prediction of Neoadjuvant Efficacy For Rectal Cancer Based On MR Cytometry Imaging and Deep-radiomics
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Rectal Cancer, Adenocarcinoma. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Study On The Prediction of Neoadjuvant Efficacy And Heterogeneity For Rectal Cancer Based On MR Cytometry Imaging and Deep-radiomics
Overview
This study employed MR cytometry imaging combined with deep-radiomic research methods to predict the heterogeneity of rectal cancer, and constructed a model to predict the sensitivity to neoadjuvant therapy and potential mechanisms, assisting clinicians in early identification of high-risk tumors and patients with treatment-susceptible rectal cancer, and selecting individualized treatment plans, thereby improving patient prognosis. To this end, the investigators need to collect the clinical diagnosis and treatment data of patients, surgical and biopsy pathological information, pre-treatment rectal MRI images and colonoscopy biopsy tissue sections, and follow up on the surgical pathological results and recurrence of patients. This study is a non-interventional diagnostic study, which does not interfere with the routine diagnosis and treatment of patients, does not affect any medical rights of patients, and does not increase any medical risks.
Primary outcome measures
- Pathological complete response [Time frame: One month after surgery]
- Pathological tumor regression grade [Time frame: One month after surgery]
- progression-free survival [Time frame: From date of surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months]
Secondary outcome measures (1)
- Pathological differentiation grade [Time frame: One month after surgery]
Eligibility criteria
Inclusion criteria
- Newly diagnosed rectal adenocarcinoma without previous treatment
- Complete radical surgery in the institute
- Complete rectal MRI within 2 weeks before surgery
Exclusion criteria
- Concomitant malignancies or systemic disease
- Inadequate MR image quality for analysis
- Incomplete clinicopathological data
- Loss of follow-up
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences — Beijing
Publications
- Zhao Q, Shi D, Zhong H, Jin C, Wang Z, Shi Z, Li L, Wang B, Jiang Y, Feiweier T, Xu J, Guo H, Zhang H. The predictive value of MR cytometry in histological differentiation of rectal cancer: an exploratory study. Eur Radiol. 2026 Jun;36(6):5155-5168. doi: 10.1007/s00330-026-12341-w. Epub 2026 Jan 30. PMID 41617831
Identifiers
NCT: NCT07107815 · NCC2025C-250